5-氯-1-丙基吲哚 | 820210-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-氯-1-丙基吲哚
• 英文名称: 5-chloro-1-propyl-1H-indole
• 英文别名: 5-chloro-1-propylindole
• CAS: 820210-24-0
• 化学式: C₁₁H₁₂ClN
• 分子量: 193.676
• InChiKey: VSOKLEMRXYURCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  5-氯吲哚 、 溴丙烷 在 caesium carbonate 作用下， 以 various solvent(s) 为溶剂， 以75%的产率得到5-氯-1-丙基吲哚
  参考文献：
  名称：

  Cesium Carbonate Promoted N-Alkylation of Indoles

  摘要：

  报告了在 DMPU 中使用碳酸铯作为碱，用烷基卤化物和环氧化物对吲哚进行 N- 烷基化反应的情况。

  DOI：

  10.1055/s-2004-832836

文献信息

• Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
  申请人：The United States of America, as represented by the Secretary, Department of Health & Human Services

  公开号：US10905769B2

  公开（公告）日：2021-02-02

  The description provides novel compounds that may serve as anticancer therapeutics. The compounds of the description bind to polo-like kinases through the polo-box domain. The peptide derivatives of the description have achieved improved efficacy in biochemical assays against Plk1. Exemplary compounds of the description include macrocyclic peptidomimetics with high affinity and selectivity for polo-like kinases, which may provide the basis for a new genre of anticancer therapeutics. Other exemplary compounds of the description include bi-valent compounds with that bind to polo-like kinases through both kinase domain and polo-box domain simultaneously by incorporating additional moieties that target Plk1 kinase domain, which significantly enhances affinitity relative and may provide the basis for a new genre of anticancer therapeutics. The description also provides methods of use, methods of preparation, compositions, and kits thereof. Further, the description provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.

  说明提供了可用作抗癌疗法的新型化合物。所述化合物通过 polo-box 结构域与 polo-like 激酶结合。描述中的肽衍生物在生化试验中对 Plk1 的疗效有所提高。本发明的示例化合物包括对polo-like激酶具有高亲和力和选择性的大环肽拟化物，可为新型抗癌疗法奠定基础。本发明的其他示例化合物包括双价化合物，它们通过加入靶向 Plk1 激酶结构域的附加分子，同时通过激酶结构域和 polo-box 结构域与 polo-like 激酶结合，从而显著增强了亲和性，并可为新型抗癌疗法奠定基础。说明还提供了使用方法、制备方法、组合物及其试剂盒。此外，该描述还提供了一种设计和/或合成可用作治疗剂的磷酸衍生肽衍生物的新方法。
• INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF
  申请人：Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.

  公开号：EP3405454B1

  公开（公告）日：2021-12-29
• [EN] PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE<br/>[FR] PEPTIDES ET PEPTIDES MIMÉTIQUES ANTAGONISTES DE LIAISON DE DOMAINE POLO-BOX DE KINASE 1 DE TYPE POLO ET PROCÉDÉ D'UTILISATION
  申请人：THE US SECRETARY DEPT OF HEALTH & HUMAN SERVICES

  公开号：WO2017082924A1

  公开（公告）日：2017-05-18

  The description provides novel compounds that may serve as anticancer therapeutics. The compounds of the description bind to polo-like kinases through the polo-box domain. The peptide derivatives of the description have achieved improved efficacy in biochemical assays against Plk1. The description also provides methods of use, methods of preparation, compositions, and kits thereof. Further, the description provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.
• Cesium Carbonate Promoted N-Alkylation of Indoles
  作者：David M. Fink

  DOI：10.1055/s-2004-832836

  日期：——

  The N-alkylation of indoles with alkyl halides and epoxides, using cesium carbonate as the base in DMPU, is reported.

  报告了在 DMPU 中使用碳酸铯作为碱，用烷基卤化物和环氧化物对吲哚进行 N- 烷基化反应的情况。